Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Recce secures A$85m R&D backing as Phase 3 nears Recce Pharmaceuticals (ASX: RCE) hit a one-week high after landing an A$85 million Advanced Overseas Finding from AusIndustry. This ruling is…

ByUjjwal Maheshwari

06

May 2025

Biotech Stocks Healthcare Stocks

This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Phase 3 ASX biotech that is close to unlocking its market opportunity. It is expecting to complete its Phase 3 trials during FY26 (the…

ByNick Sundich

19

Feb 2025

Healthcare Stocks Life Sciences Small Caps Stocks

Recce’s R327G passed its Phase 2 trial with a 93% primary efficiacy endpoint!

Recce Pharmaceuticals (ASX:RCE) has completed its Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections) for RECCE® 327 Topical Gel (R327G) and released the results earlier this week.…

ByNick Sundich

10

Feb 2025

Education Life Sciences

Here’s how Australia’s Research and Development Tax Incentive Works

Australia's Research and Development Tax Incentive (R&D Tax Incentive) regime can be useful for pre-commercialisation companies serving as a non-dilutive source of funding. Progressing new medical treatments or technologies to market…

ByNick Sundich

21

Jan 2025

Healthcare Stocks

Here are 3 ASX stocks fighting diabetes and the opportunity ahead of them

There aren't many ASX stocks fighting diabetes, but the few that are have a big market opportunity ahead of them. And they are not just about fighting the condition directly but…

ByNick Sundich

06

Nov 2024

Healthcare Stocks Life Sciences Mid Cap Stocks Small Caps Stocks

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

There are encouraging signs from Recce Pharmaceuticals' (ASX:RCE) Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections). The trial, is nearing completion, but the results to date…

ByNick Sundich

15

Oct 2024

Healthcare Stocks Life Sciences

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons why. For many companies, the golden market has been the USA,…

ByNick Sundich

23

Aug 2024

Healthcare Stocks

Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval

The list of major milestones of ASX biotech companies is headed with clinical trial results, regulatory approval and commercialisation. However, clinical trials can take a long time, and there are…

ByNick Sundich

22

Aug 2024

Healthcare Stocks

Recce Pharmaceuticals investors are excited despite the market volatility – and there’s good reason

Recce Pharmaceuticals investors are amongst the few investors in ASX stocks that have a reason to smile right now. Their company has significantly outperformed the broader ASX, sitting in positive…

ByNick Sundich

30

Jul 2024

Healthcare Stocks Small Caps Stocks

These ASX biotechs are working with the US Department of Defence to bring new drugs to market and have a bright future ahead

Think of ASX stocks working with the US Department of Defence, and investors might imagine defence stocks or perhaps even critical mineral project developers. This is not completely untrue. The list…

ByNick Sundich

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn

Recce’s R327G passed its Phase 2 trial with a 93% primary efficiacy endpoint!

Here’s how Australia’s Research and Development Tax Incentive Works

Here are 3 ASX stocks fighting diabetes and the opportunity ahead of them

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval

Recce Pharmaceuticals investors are excited despite the market volatility – and there’s good reason

These ASX biotechs are working with the US Department of Defence to bring new drugs to market and have a bright future ahead

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here